The short answer
Chromium may add to insulin’s glucose-lowering effect, so review and monitoring are reasonable with insulin degludec. A degludec-specific risk rate or chromium requirement has not been established.
What this answer covers
Trivalent oral chromium supplements; picolinate study does not represent every salt or industrial hexavalent chromium.
- Supplement or preparation
- Chromium
- Medication ingredient
- insulin degludec
Federal guidance supports a precaution
NIH guidance cautions that chromium may enhance glucose lowering with insulin. Tresiba likewise calls for review when glucose-active treatments change. This is a conditional precaution rather than an exact interaction rate.
The drug trial used glipizide
A chromium-picolinate study improved glucose measures and insulin sensitivity during glipizide GITS treatment. Glipizide is an oral insulin secretagogue, so its results cannot quantify the risk with injected degludec.
No chromium requirement follows
The trial does not show that degludec depletes chromium or that all insulin users should supplement. Form, elemental amount and overlapping products matter.
Do not invent a protective gap
Discuss the exact product and amount with the diabetes team and follow your glucose-monitoring and low-glucose treatment plan. Do not adjust insulin yourself. No short supplement-spacing interval is established to remove a possible glucose effect.
Evidence and practical considerations
Side effects & toxicity
Federal chromium-insulin precaution supports individual monitoring; clinical study was glipizide, not degludec, and does not establish a nutritional requirement.
- Exact scope
- Trivalent oral chromium supplements; picolinate study does not represent every salt or industrial hexavalent chromium. with insulin degludec RxCUI1670007 IN; single-insulin subcutaneous product, concentration and schedule specific.
- Medication form and route
- subcutaneous insulin degludec; oral supplement
What remains uncertain
- No exact event rate or arbitrary insulin change.
Factors that may matter: Product; Dose; Meals; Other diabetes treatment; Kidney and liver function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed TRESIBA
Hypoglycemia can be severe; meal, activity and glucose-active treatment changes can require increased monitoring and clinician review. No intravenous or pump use. Adults once daily at any time; children same time daily. Adult missed-dose8hour injection interval is not supplement-spacing advice.
How this applies: Exact insulin degludec RxCUI1670007 IN, single-insulin product scope. Combination products not assumed equivalent.
No exact supplement interaction rate. Long-acting insulin is not a rapid mealtime formulation; concentration and device matter.
Source 2: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Adults with type 2 diabetes.
Chromium group had improved insulin sensitivity and glycemic control; the abstract does not provide a hypoglycemia event rate.
How this applies: Indirect for exact insulin degludec; original study drug, preparation and endpoint retained.
Trial used glipizide GITS, not insulin degludec. No exact insulin-combination event rate or chromium requirement established.
Source 3: federal health guidance
ods.od.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Chromium may add to glucose-lowering effects of diabetes medicines; clinical benefit is inconsistent. No established glipizide-induced requirement.
How this applies: Indirect for exact insulin degludec; original study drug, preparation and endpoint retained.
Federal insulin-class precaution, not an exact insulin degludec trial or universal chromium need.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact basal-insulin article with independently inspected product labels and original endpoint limits. | |
| Research summary published |
Article revision: de5817208d2bf139
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.